These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15124199)

  • 21. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies.
    Cao W; Krishnan S; Ricci MS; Shih LY; Liu D; Gu JH; Jameel F
    Eur J Pharm Biopharm; 2013 Oct; 85(2):287-93. PubMed ID: 23702275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A step toward development of printable dosage forms for poorly soluble drugs.
    Raijada D; Genina N; Fors D; Wisaeus E; Peltonen J; Rantanen J; Sandler N
    J Pharm Sci; 2013 Oct; 102(10):3694-704. PubMed ID: 23904182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
    Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation development and stability testing of oral morphine solution utilizing preformulation approach.
    Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T
    J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.
    Saluja A; Badkar AV; Zeng DL; Kalonia DS
    J Pharm Sci; 2007 Dec; 96(12):3181-95. PubMed ID: 17588261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
    Yi T; Wan J; Xu H; Yang X
    Eur J Pharm Sci; 2008 Aug; 34(4-5):274-80. PubMed ID: 18541418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of cryogenic grinding on properties of a self-emulsifying formulation.
    Chambin O; Jannin V; Champion D; Chevalier C; Rochat-Gonthier MH; Pourcelot Y
    Int J Pharm; 2004 Jun; 278(1):79-89. PubMed ID: 15158951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New analytical techniques to facilitate preformulation screening in propellant systems.
    Mogalian E; Kuehl PJ; Myrdal PB
    Int J Pharm; 2007 Aug; 340(1-2):223-9. PubMed ID: 17498897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of process analytical technology for monitoring freeze-drying of an amorphous protein formulation: use of complementary tools for real-time product temperature measurements and endpoint detection.
    Schneid SC; Johnson RE; Lewis LM; Stärtzel P; Gieseler H
    J Pharm Sci; 2015 May; 104(5):1741-9. PubMed ID: 25691354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application.
    Kasper JC; Schaffert D; Ogris M; Wagner E; Friess W
    J Control Release; 2011 May; 151(3):246-55. PubMed ID: 21223985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of nanotechnology in pharmaceutical product development.
    Devalapally H; Chakilam A; Amiji MM
    J Pharm Sci; 2007 Oct; 96(10):2547-65. PubMed ID: 17688284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Jan; 102(1):62-72. PubMed ID: 23150484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and bioavailability assessment of ramipril nanoemulsion formulation.
    Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
    Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y; Porter W; Merdan T; Li LC
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release.
    Maroni A; Del Curto MD; Serratoni M; Zema L; Foppoli A; Gazzaniga A; Sangalli ME
    Eur J Pharm Biopharm; 2009 May; 72(1):246-51. PubMed ID: 19121388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.
    Kinnunen HM; Mrsny RJ
    J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V; Musakhanian J; Marchaud D
    Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevant shaking stress conditions for antibody preformulation development.
    Eppler A; Weigandt M; Hanefeld A; Bunjes H
    Eur J Pharm Biopharm; 2010 Feb; 74(2):139-47. PubMed ID: 19922795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.